Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.77 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 3/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.52 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | AGXT | P21549 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810530 | 0.93 | MAOB (0.77) | MAOBMRGPRX4NPC1ALDH1A1RAB9A | |
| SCHEMBL4404036 | 0.88 | MAOB (1.00) | MAOBMRGPRX4NPC1ALDH1A1RAB9A | |
| SCHEMBL29666660 | 0.82 | MAOB (1.00) | MAOBMRGPRX4NPC1ALDH1A1RAB9A | |
| SCHEMBL73864 | 0.82 | MAOB (1.00) | MAOBMRGPRX4NPC1ALDH1A1RAB9A | |
| SCHEMBL631673 | 0.82 | MAOB (0.79) | MAOBRAB9ASMN1; SMN2MAOAAPP | |
| SCHEMBL31114416 | 0.82 | MAOB (0.79) | MAOBRAB9ASMN1; SMN2MAOAAPP | |
| SCHEMBL810677 | 0.81 | MAOB (0.72) | MAOBMAOAAPP | |
| SCHEMBL3321461 | 0.81 | MAOB (0.69) | MAOBRAB9ASMN1; SMN2MAOAPARP15 | |
| SCHEMBL17978716 | 0.81 | MAOB (0.96) | MAOBMRGPRX4NPC1ALDH1A1RAB9A | |
| SCHEMBL16795515 | 0.80 | MAOB (1.00) | MAOBMRGPRX4NPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-101443334-A | Anti-viral compounds | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAOB 3352/4885MRGPRX4 3393/4885NPC1 37/4885 |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAOB 3352/4885MRGPRX4 3393/4885NPC1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.